Marsal JR, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights. Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Sebastian J, Cai l, Williamson D, Foushee B, Kam-Morgan L, Eisenberg MT. Identification and characterization of two novel sequence variants in the Thrombopoietin Receptor (MPL) gene using data from 8700 JAK-2 V617F negative patients. Poster presented at the 2016 Association for Molecular Pathology (AMP) Annual Meeting; November 10, 2016. Charlotte, NC. [abstract] J Mol Diagn. 2016 Nov; 18(6):955. doi: 10.1016/S1525-1578(16)30176-3
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Bartha E, Davidson T, Brodtkorb T, Carlsson P, Kalman S. Value of information: interim analysis of a randomized, controlled trial of goal-directed hemodynamic treatment for aged patients. Trials. 2013 Jul 9;14:205.